SUPPLEMENTARY MATERIALS

Defining Heart Failure Endpoint in ATTR Amyloidosis Clinical Trials - time for an update?

D.Gjermeni[1], Kevin M. Alexander[1,2], James L. Januzzi[2], K. W. Mahaffey[1]

[1]Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine; Stanford, CA, USA

[2]Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA

[3]Baim Institute for Clinical Research, Harvard Medical School, Massachusetts General Hospital; Boston, MA, USA

Address of Correspondence:
Diona Gjermeni
Stanford Center for Clinical Research
3180 Porter Drive,
Palo Alto, CA, 94304
gjermeni@stanford.edu
650.888.9228

Supplemental material

Survey of Adjudicator Challenges in HF Diagnosis Across Clinical Trials*

1. **Was it challenging to apply the HF definition from the study Charter to the cases that were reviewed?**
    1. Yes
    2. No *If yes, please provide some specific challenges* _____

2. **What was the most commonly missing information to define HF event:**
    1. Clinical symptoms
    2. Signs from clinical exams
    3. Laboratory parameters (proBNP)
    4. Imaging parameters (LVEF worsening, chest imaging)
    5. Changes in diuretic treatment

3. **Were the adjudication forms easy to complete?**
    1. Yes
    2. No

    *If no, please provide some examples of changes you would make*_____

** This survey was developed by the authors and was not a validated instrument, but rather an informal tool designed to gather exploratory information on adjudicator-reported difficulties in heart failure adjudication*.